RARE Daily

Synthego Raises $200 Million to Accelerate the Field of CRISPR-Based Medicines

February 17, 2022

Genome engineering tools company Synthego raised $200 million to accelerate the creation of a cell and gene therapy discovery and development ecosystem to help researchers scale and simplify the translation of new discoveries into novel therapeutics for serious diseases.

Photo: Paul Dabrowski, co-founder and CEO of Synthego

The capital includes a series E financing led by Perceptive Advisors with participation by new investors SoftBank Vision Fund 2, Declaration Partners, Laurion Capital Management, Logos Capital, GigaFund and Chimera Abu Dhabi, and existing investors Wellington Management, RA Capital Management and Moore Strategic Ventures.

“CRISPR has become a powerful discovery tool, and the field is now at an inflection point. The promise of translating insights into clinical applications to treat a myriad of serious diseases, including cancer and genetic disorders, is within reach,” said Paul Dabrowski, co-founder and CEO of Synthego. “With Synthego’s full stack of proprietary platforms, clinical-grade manufacturing capabilities, and strong relationships in industry, academia and the investor community, we are well positioned to help our customers usher in this new era of genetic and cellular medicines, ultimately ensuring these therapies are accessible to all patients.”

Synthego plans to expand both the capacity and capabilities of its Halo and Eclipse Platforms for research and discovery applications, continuing to drive broad accessibility of genome engineering tools and genome engineered cells. Synthego will also invest in next-generation technologies such as CRISPROff, a light-based system for specific and precise CRISPR editing, and increase its Good Manufacturing Practice (GMP) manufacturing capabilities to support its customers’ clinical and therapeutic programs.

The development of next-generation CRISPR-based cellular and genetic medicines requires the ability to rapidly discover new biology, deploy advanced bioinformatics, optimize and perform precision genome editing, and seamlessly translate from research into clinical settings. Synthego says its vertically integrated approach, with continued investments in extensive genome engineering capacity, machine learning-based optimizations, proprietary high throughput manufacturing hardware and software, and an expanding precision genome editing tool kit, is providing customers and partners with an increasingly comprehensive path to discovering, developing, optimizing and manufacturing novel CRISPR-based cell and gene therapies.

Author: Rare Daily Staff

Stay Connected

Sign up for updates straight to your inbox.